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ABSTRACT
Background: The definition of remission in systemic
lupus erythematosus (SLE) remains unclear, especially
how background treatment should be interpreted.
Objective: To determine preferences of clinicians in
treatment of patients in clinical remission from SLE
and to assess how previous severity, duration of
remission and serology influence changes in treatment.
Methods: We undertook an internet-based survey of
clinicians managing patients with SLE. Case scenarios
were constructed to reflect different remission states,
previous organ involvement, serological abnormalities,
duration of remission and current treatment
(hydroxychloroquine (HCQ), steroids and/or
immunosuppressive (ISS) agents).
Results: 130 clinicians from 30 countries were
surveyed. The median (range) duration of practice and
number of patients with SLE seen each month was 13
(2–42) years and 30 (2–200), respectively. Management
decisions in all scenarios varied with greater caution in
treatment reduction with shorter duration of remission,
extent of serological abnormalities and previous disease
severity. Even with mild disease, normal serology and a
5-year clinical remission, 113 (86.9%) clinicians
continue to prescribe HCQ. Persistent abnormal
serology in any scenario led to a reluctance to reduce or
discontinue medications. Prescribing in remission,
particularly of steroids and HCQ, varied significantly
according to geographical location.
Conclusions: Clinicians preferences in withdrawing or
reducing treatment in patients with SLE in clinical
remission vary considerably. Serological abnormalities,
previous disease severity and duration of remission all
influence the decision to reduce treatment. It is unusual
for clinicians to stop HCQ even after prolonged periods
of clinical remission. Any definition(s) of remission
needs to take into consideration such evidence on how
maintenance treatments are managed.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a
prototypical autoimmune disease charac-
terised by alternating periods of disease activ-
ity and quiescence. The main aim of
treatment is to control inﬂammatory disease
activity and prevent ﬂares of disease while in
remission.1 The mortality and morbidity asso-
ciated with SLE have improved signiﬁcantly
over the past 50 years owing to introduction
of treatments such as corticosteroids, anti-
malarial agents (AMs), immunosuppressive
(ISS) drugs and more recently, biological
agents. Although such treatments have
improved disease control, all are associated
with potential long-term sequelae that can
adversely affect patient outcomes and thus
patients should be maintained on the
minimum long-term treatment necessary to
satisfactorily control disease.2 Studies have
shown that while up to 17% of patients with
SLE may successfully stop all medications for
a period of time, only 1% of patients will suc-
cessfully continue without all medications for
≥5 years and have no clinical or serological
disease activity during that time.3
Efforts to deﬁne particular disease ‘states’
in SLE are of value for physicians looking
after patients but also for the research com-
munity to enable better stratiﬁcation of
patients, thus allowing researchers to stand-
ardise comparisons across cohorts. A few
years ago, lupus experts reached a consensus
about a deﬁnition of lupus ﬂare.4 The
treat-to-target (T2T) initiative has also pro-
vided a framework of principles to consider
when treating SLE.5 A key recommendation
of this initiative is that remission is the key
‘treatment target’ and, if not achievable,
then low disease activity should be targeted.5
However, at present there is no clear consen-
sus about what constitutes remission in SLE.
In particular, there is a lack of agreement
about how background treatment should
affect any potential deﬁnition of remission.
A number of guidelines for the treatment
of active SLE exist. In contrast, there is little
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guidance about how and when to decrease or stop medi-
cation in patients with SLE.5–9 Physicians’ approaches to
reducing treatment remain undeﬁned. It is unclear
which factors inﬂuence this decision (eg, previous
disease phenotype, current serology) or the order in
which drugs are withdrawn and whether AMs are ever
reduced or withdrawn in routine practice. Knowledge of
physicians’ habits and opinions is important so that any
deﬁnition of remission can be pragmatically applied
both in the clinic and in future studies.
We aimed to survey clinicians caring for patients with
SLE to determine how background treatment is
managed during clinical remission. In particular, we
aimed to study how previous SLE severity, duration of
remission and serology inﬂuence changes in treatment
and to determine the usual order of drug reduction
and/or withdrawal in usual care.
METHODS
Survey creation
The survey was developed by two consultant rheumatolo-
gists (INB, BP) and a clinical fellow (PN) with extensive
experience in the management of SLE based on ‘real-
life’ clinical scenarios. The initial draft was piloted on
additional rheumatologists experienced in the manage-
ment of SLE ( JR, SS) and then adjusted. After altera-
tions the ﬁnal survey was reviewed, agreed by all and
disseminated as an internet-based survey (Select Survey.
NET) aimed at clinicians involved in the management
of SLE. Thirty case scenarios were constructed to reﬂect
a range of potential ‘states’ of clinical remission. These
were grouped into seven ‘stems’ with one stem repre-
senting minor organ involvement—for example, joint
and skin only; the other six stems represented patients
with major organ involvement—for example, renal and
neuropsychiatric (see online supplementary data 1). In
all cases the patient was said to have “no evidence of any
organ involvement, have a normal eye examination and
a normal full blood count, renal proﬁle, inﬂammatory
markers and urinary examination”. Within each stem we
then added variations based on duration of remission
(1, 3 or 5 years), current serological abnormalities (pres-
ence or absence of high anti-dsDNA antibodies and/or
low/normal complement levels), number of previous
ﬂares (single or multiple) and currently prescribed treat-
ment (hydroxychloroquine (HCQ), steroids and/or ISS
agents). Respondents were asked to indicate whether
they would continue, reduce or withdraw each medica-
tion type in each scenario.
Minor organ involvement stem
A 26-year-old woman with a 10 year history of SLE (rash,
arthritis) with no clinical disease activity for the past
5 years was the model to assess how clinicians would deal
with a patient who had only ever had mild disease and
no evidence of clinical disease activity for a long period
of time. A key aim of this ‘stem’ was to determine what
low-dose treatment clinicians would use in such patients.
We devised six associated scenarios comprising combina-
tions of serological abnormality (complement low/
normal and/or anti-dsDNA high/normal either alone
or in combination) and one of three types of current
medication regimens:
1. HCQ 200 mg alone;
2. HCQ 200 mg plus prednisolone 5 mg;
3. HCQ 200 mg, prednisolone 5 mg and methotrexate
(MTX) 7.5 mg weekly.
Major organ involvement stems
A 26-year-old woman with a previous history of lupus
nephritis (class IV) and neuropsychiatric involvement
was the subject of the scenario for the major organ
stems. A total of 24 scenarios were created reﬂecting
combinations of the number of previous ﬂares (single vs
multiple), duration of remission (1, 3, 5 years) and sero-
logical abnormalities as outlined in the minor organ
stem.
Participant recruitment
To identify clinicians with an interest in SLE, the survey
link was sent to (i) corresponding authors of papers
from Lupus journal published between January 2013 and
December 2013 and (ii) international lupus working
groups, including the British Isles Lupus Assessment
Group, Systemic Lupus International Collaborating
Clinics and the Thai Rheumatology Association.
Clinicians were asked about their specialty, duration of
practice, number of patients with SLE seen each month
and geographical location.
Statistical analysis
The number and proportion of respondents indicating
whether to continue, reduce or withdraw each type of
medication was calculated for each scenario. The associ-
ation between case characteristics (number of ﬂares,
duration of absence of clinical disease activity, sero-
logical changes) and participant decisions about medica-
tion use was assessed using χ2 tests. Statistical tests were
considered to be signiﬁcant at p<0.05.
Ethics
This study was approved by the University of Manchester
research ethics committee (reference number 13287).




We contacted 185 clinicians, of whom 54 replied to our
ﬁrst email. After 2 weeks a second reminder email was
sent to all participants. In total we received responses
from 130 clinicians (response rate 70%), most of whom
were rheumatologists (n=113/130, 86.9%). Response
rates differed according to region, with a majority of
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responses from European (n=54, 41.5%) and Asian
(n=53, 40.8%) physicians and a minority from North
America (n=16, 12.3%). The median (range) duration
of practice was 13 (2–42) years and 30 (2–200) patients
with SLE were seen each month.
Minor organ involvement scenario: approach to HCQ use
Physicians rarely withdraw HCQ whatever the clinical
scenario. For example, in the scenario within stem 1
where the patient with previous mild disease was
described as having a 5-year clinical remission, normal
serology for the entire duration of that period and was
taking HCQ 200 mg daily alone (ie, the mildest disease
of all the scenarios), only 13% of physicians (n=16/120)
indicated that they would withdraw the drug.
Physicians preferred order for medication reduction in mild
disease: approach to prednisolone
When HCQ was used in combination with steroids and/
or MTX to control mild disease, it was also the least likely
drug to be altered. In this scenario clinicians were more
likely to maintain the current dose of HCQ and reduce
either the steroid and/or MTX dose, with this trend
being true for those with both normal and abnormal ser-
ology (see online supplementary data 1—Stem 1).
Prednisolone was the ﬁrst medication that physicians
suggested reducing or withdrawing during any pro-
longed remission, irrespective of whether it was used
with HCQ alone or as part of a regimen involving
prednisolone, HCQ and MTX. For example, after
5 years’ remission in a serologically quiescent patient,
taking HCQ and prednisolone only, 116 (96.7%) pre-
ferred to reduce or withdraw steroids. Similarly, 110
(90.9%) preferred to alter steroids if used in combin-
ation with both HCQ and MTX for the same clinical
scenario (ﬁgure 1).
Major organ involvement: neuropsychiatric SLE, class IV
lupus nephritis
Drug reduction or withdrawal
For the management scenarios of patients with SLE with
major organ involvement, the preferred order of redu-
cing or withdrawing drugs was the same as for mild
disease, with physicians most likely to suggest altering
steroid doses ﬁrst, followed by ISS agents, with AMs
being reduced or withdrawn infrequently (ﬁgure 2). For
example, (see online supplementary data 1—Stem 4)
when a patient with previous major organ disease had
been stable for 5 years and had normal serology, 94
(93.1%) respondents would plan to reduce or withdraw
steroids, 53 (52.5%) would plan to reduce or withdraw
the ISS and only 16 (15.8%) would reduce or withdraw
HCQ.
Duration of stable disease
Where patients had stable, serologically inactive disease
after a previous ﬂare (stems 2–4), at 1 year the vast
majority of physicians (92.4%, n=109/118) planned to
reduce (74.6%, n=88) or completely withdraw (17.8%,
n=21) steroids; this number was similar for remission
duration of 3 or 5 years (3 years: 91%; 5 years: 93%).
When speciﬁcally asked about withdrawing steroids from
patients, physicians were more inclined to completely
withdraw prednisolone treatment with longer duration
of remission (ﬁgure 3).
Figure 1 Pattern of alteration of medications by physicians
in a patient with mild SLE (skin and joint only), no evidence of
clinical disease activity for 5 years and current normal
serology according to the patients’ baseline medication
regimen. The three scenarios vary according to the drug
combination the patient is taking. HCQ, hydroxychloroquine;
MTX, methotrexate; Pred, prednisolone.
Figure 2 The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major
organ involvement from their SLE (renal and neuropsychiatric) in clinical remission for 5 years with no evidence of current
serological activity. The four scenarios vary according to the serological abnormality. N/N, normal dsDNA/normal complement; P/
N, abnormal dsDNA/normal complement; N/P, normal dsDNA/abnormal complement; P/P, abnormal dsDNA/abnormal
complement; HCQ, hydroxychloroquine; ISS, immunosuppressive.
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In contrast, HCQ withdrawal or reduction was rarely
initiated irrespective of the remission duration: a prefer-
ence to reduce or withdraw HCQ was stated by only 6
(8.5%) physicians at 1 year, 14 (12.5%) at 3 years and 16
(15.5%) at 5 years’ stability for the same clinical scen-
ario. Similarly, the vast majority of physicians opted to
continue ISS agents across the times assessed. However,
in those who did aim to withdraw ISS agents a longer
duration of remission appeared to inﬂuence their
intended practice—for example, 5 (4%) would withdraw
ISS after 1 year of stable disease compared with 12 (11%)
after 3 years and 22 (22%) after 5 years (ﬁgure 3).
Serological abnormalities
Serological abnormalities signiﬁcantly inﬂuenced the
physicians’ approach to treatment even in mild disease.
For example, as outlined in the ﬁrst scenario presented
above, 104/120 (86.7%) physicians preferred to con-
tinue HCQ even after 5 years’ remission in mild disease,
with 38 (31.7%) opting to continue HCQ at the same
dose and 66 (55%) reducing the dose. Interestingly,
when the same patient was described as having abnor-
mal serology, a signiﬁcant change in their intention
towards treatment was noted despite the patient being in
clinical remission for 5 years. Respondents were signiﬁ-
cantly less likely to taper the HCQ dose, with 82/117
(70.1%) continuing the same dose, 31 (26.5%) reducing
the dose and only 4 (3.4%) aiming to withdraw the drug
(p<0.01 vs previous scenario).
As with mild disease, the presence of active serology
had a signiﬁcant inﬂuence on physicians’ decisions
across a range of scenarios in patients with a previous
history of major organ involvement (ﬁgure 4). In par-
ticular, we found that having both low complement and
high antibodies to dsDNA signiﬁcantly inﬂuenced the
future plans for all drug classes at all time-points, with
the exception of HCQ at 1 year in patients who had a
single major ﬂare, where over 90% of physicians would
plan to continue the same dose anyway (stem 2). For
example, after 5 years of stable disease in a patient with
a single major ﬂare previously (stem 4), in the presence
of both low complement and high antibodies to dsDNA,
Figure 3 Longer duration of clinical remission is associated with increased likelihood of withdrawal of prednisolone and ISS
drugs in a patient with SLE with previous major organ involvement and current normal serology. The four scenarios vary
according to serological abnormality. N/N, normal dsDNA/normal complement; P/N, abnormal dsDNA/normal complement; N/P,
normal dsDNA/abnormal complement; P/P, abnormal dsDNA/abnormal complement; ISS, immunosuppressive.
Figure 4 The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major
organ involvement from their SLE (renal and neuropsychiatric) in clinical remission for 1, 3 or 5 years is influenced by the
presence of current serological activity (stems 2–4). The four scenarios vary according to the serological abnormality presented
to the physician. N/N, normal dsDNA/normal complement; P/N, abnormal dsDNA/normal complement; N/P, normal dsDNA/
abnormal complement; P/P, abnormal dsDNA/abnormal complement; ISS, immunosuppressive. Antimalarial agents,
prednisolone, immunosuppressive drugs: CCC, continue, continue, continue; CRC, continue, reduce, continue; CRR, continue,
reduce, reduce; CWC, continue, withdraw, continue; CWW, continue, withdraw, withdraw. HCQ, hydroxychloroquine.
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5/102 (4.9%) physicians would suggest a reduction or
withdrawal of HCQ compared with 16 (15.7%) when the
serology was normal (p=0.048).
For steroids and ISS agents in the same scenario (stem
4) the rates of reduction or withdrawal when both sero-
logical abnormalities were present compared with normal
serology were 58% (n=59) vs 92% (n=94) (p<0.001) and
22% (n=22) vs 52% (n=53), (p<0.001), respectively. Thus,
more than 40% of clinicians preferred to continue ster-
oids with almost 80% expressing a preference towards
continuing additional ISS without dose reduction in sero-
logically active (both anti dsDNA and low complement)
clinically quiescent patients even when the duration of
clinical remission was 5 years (ﬁgure 4).
Examination of the contribution of the individual
serological abnormalities showed that low complement
levels signiﬁcantly affected a physician’s decision about
drug treatment in 14 of 18 scenarios. In contrast, 5 of a
potential 18 drug changes were signiﬁcantly inﬂuenced
by having high antibodies to dsDNA as the only sero-
logical abnormality.
Frequency of disease flare
We found that one previous major ﬂare or multiple ﬂares
of SLE had no clear inﬂuence on drug treatment changes.
Geographical origin of the physician
Prescribing for patients in remission, particularly of ster-
oids, varied geographically. For example, in the case of
stable, mild disease for 5 years, steroids would be
stopped by 24 (48%) European respondents, 4 (28.6%)
North American respondents and 10 (19.6%) Asian phy-
sicians (p=0.04). In addition, for severe disease,
Europeans were more likely to continue HCQ than
Asian physicians, who preferred to reduce dosage in
most scenarios (table 1) as reﬂected by the scenario of
the patient with previously severe disease, now stable for
5 years. In this case 40 (93.0%) European respondents
would continue HCQ compared with 31 (73.8%) Asian
physicians (p=0.02). In contrast, and similar to the
results observed in mild disease, across every timepoint
assessed European physicians would be more likely to
stop steroid treatment than their Asian counterparts
(1 year: 8/48 vs 4/49 (p=0.38), 3 years: 20/46 vs 5/47
(p<0.001), 5 years: 21/43 vs 7/42 (p=0.002)), highlight-
ing a geographical variation in approach to medication
withdrawal. Neither duration of practice nor the
number of patients seen monthly by physicians was
found to signiﬁcantly inﬂuence clinical practice and the
decision to discontinue or continue steroids or continue
HCQ across the various stems analysed.
DISCUSSION
We studied clinicians’ opinions on management of clin-
ical remission in patients with SLE across a range of
hypothetical scenarios with different organ involvement,
duration of clinical remission and serological results.
Our ﬁndings suggest that clinicians’ preferred practice
for continuation of medications in clinical remission are
inﬂuenced chieﬂy by the presence of serological abnor-
malities, especially when patients have both low comple-
ment and high antibodies to dsDNA, a response that is
primarily driven by low complement. We also identiﬁed
Table 1 Comparison of respondents practising in Europe
and Asia who would continue, reduce or withdraw
treatments in a patient with SLE with major organ
involvement in remission and normal serology
Europe Asia p Value
Stable for 1 year
HCQ
Continue 45/48 (93.8) 42/49 (85.7) 0.04
Reduce 1/48 (2.1) 7/49 (14.3)
Withdraw 2/48 (4.2) 0
Prednisolone
Continue 3/48 (6.3) 5/49 (10.2) 0.38
Reduce 37/48 (77.1) 40/49 (81.6)
Withdraw 8/48 (16.7) 4/49 (8.2)
Immunosuppressant agents
Continue 35/48 (72.9) 16/49 (32.7) <0.001
Reduce 11/48 (22.9) 32/49 (65.3)
Withdraw 2/48 (4.2) 1/49 (2.0)
Stable for 3 years
HCQ
Continue 44/46 (95.7) 35/47 (74.5) 0.004
Reduce 0 10/47 (21.3)
Withdraw 2/46 (4.3) 2/47 (4.3)
Prednisolone
Continue 8/46 (17.4) 3/47 (6.4) <0.001
Reduce 18/46 (39.1) 39/47 (83.0)
Withdraw 20/46 (43.5) 5/47 (10.6)
Immunosuppressant agents
Continue 23/46 (50) 17/47 (36.2) 0.07
Reduce 16/46 (34.8) 27/47 (57.4)
Withdraw 7/46 (15.2) 3/47 (6.4)
Stable for 5 years
HCQ
Continue 40/43 (93.0) 31/42 (73.8) 0.02
Reduce 1/43 (2.3) 9/42 (21.4)
Withdraw 2/43 (4.7) 2/42 (4.8)
Prednisolone
Continue 5/43 (11.6) 3/42 (7.1) 0.002
Reduce 17/43 (39.5) 32/42 (76.2)
Withdraw 21/43 (48.8) 7/42 (16.7)
Immunosuppressant agents
Continue 24/43 (55.8) 17/42 (40.5) <0.001
Reduce 5/43 (11.6) 23/42 (54.8)
Withdraw 14/43 (32.6) 2/43 (4.8)
Results are shown as number (%).
Patient was said to be in remission based on “no evidence of any
organ involvement, has a normal eye examination and a normal
full blood count, renal profile, inflammatory markers and urinary
examination”. Duration of remission was varied as indicated above
(1, 3 or 5 years) with the patient having no current serological
abnormalities (ie absence of high anti-dsDNA antibodies and
normal complement levels) and receiving currently prescribed
treatment (HCQ, steroids and immunosuppressant agents).
HCQ, hydroxychloroquine.
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clear preferences for the sequence in which drugs were
altered. Physicians prefer ﬁrst to reduce and withdraw
steroids from any therapeutic regimen, followed by ISS
drugs. HCQ is rarely discontinued. European physicians
appear more inclined to withdraw steroid treatment
altogether than their Asian counterparts.
Remission is the goal of SLE treatment.5 However,
there is no international consensus on the deﬁnition of
remission according to the inﬂuence of serology, disease
duration and medications. Owing to this lack of standard-
isation, previous studies of remission in SLE have been
characterised by a wide variety of deﬁnitions with a conse-
quential disparity in reported remission rates.3 10–13
Steiman et al12 reported that only 2% of patients had pro-
longed clinical remission at 5 years without steroid and
ISS drugs in the Toronto cohort. In contrast, the 1-year
remission rate was as high as 53% in an Italian study
when only clinical criteria were used and serology and
medications were not taken into account. This highlights
the signiﬁcant confounding inﬂuence of medications and
serological investigations on any consensus deﬁnition of
remission in SLE.3 13
In our survey we found that even after 5 years of clin-
ical remission in patients with a history of major organ
involvement, 40% of physicians preferred to continue
steroids and 80% ISS unaltered if any evidence of active
serology was seen. It might be argued that any beneﬁcial
effect from continued medication administration in pre-
venting ﬂares in this population might be outweighed by
the disadvantages of prolonged use of ﬁxed treatments,
all with well-recognised side effects, without obvious clin-
ical need. Steiman et al followed up patients who had
sustained serologically active, clinically quiescent disease
for more than 2 years and reported that approximately
40% continued to be clinically quiescent throughout the
follow-up period.14 Our observation of physician behav-
iour therefore suggests that a population of patients with
SLE exists for whom continued use of treatment may
not have any real beneﬁt. Further studies and trials are
needed to determine the true risks and beneﬁts of con-
tinuing or withdrawing treatment and current clinical
trials, such as the National Institute of Allergy and
Infectious Diseases sponsored mycophenolate mofetil
withdrawal in SLE study (NCT 01946880), will help to
inform future clinical practice in much the same way
that the Canadian Hydroxychloroquine Study Group
demonstrated the beneﬁcial effect of AMs in the
disease.15 16
Our study showed that steroid reduction and with-
drawal is the most likely choice of physicians, irrespective
of the clinical scenario. The adverse effects of glucocor-
ticoids are well established, particularly in patients with
SLE, and our study suggests that physicians are aware of
these risks and attempt to mitigate them as early as pos-
sible once disease control is achieved.17 Nevertheless, a
signiﬁcant proportion of patients appear to be kept on
some dose of steroid by their treating physician despite
clinical remission, particularly if there is a history of
severe organ involvement. This has previously been
observed by Walsh et al18 in their study of proliferative
lupus nephritis, where approximately 30% of patients
continued to receive some dose of steroid in all scen-
arios after successful induction treatment. Our study has
highlighted key factors which determine the decision to
continue or withdraw steroids. A longer duration of
remission appeared to have a modest effect on physi-
cians’ treatment intention but the single biggest inﬂu-
ence on any decision to adjust medication was the
presence/absence of serological abnormalities, even
when there was no clinical evidence of disease activity.
Therefore, additional biomarkers, better than dsDNA
and complement (which have a poor predictive value of
impending ﬂare) are urgently needed to assist treating
physicians in identifying quiescent disease activity accur-
ately and promptly allowing safe reduction of steroids.
We also noted some regional variation in prescribing
practices, with European physicians having a greater ten-
dency to continue HCQ and withdraw steroid doses
than their Asian counterparts. Although disease severity
across regions might affect this variation, this treatment
pattern was also seen in the stem that reﬂected 5-year
remission in a patient with mild skin and joint disease.
In view of the signiﬁcant contribution of steroids to the
excess morbidity and mortality in SLE, this observation
warrants further investigation, especially as failure to
reduce/withdraw steroids beyond prespeciﬁed endpoints
can be deemed as ‘treatment failure’ in clinical trials,
which are often conducted across large geographical
regions.19 20
Current guidelines recommend using long-term AMs
in all patients with SLE unless contraindicated.5 Our
data indicate that this is now standard practice across the
geographical spread of our survey, albeit with Asian phy-
sicians more likely to taper them over time. The beneﬁts
of AMs include reduction of ﬂares, improvement of skin
manifestations, prevention of damage and possibly
reduction in mortality.16 21 Therefore, while future
guidelines and recommendations for deﬁnition(s) of
remission must be evidence based, any deﬁnition that
includes ‘drug-free’ patients will be a rare event as the
majority of doctors continue to prescribe AMs long-
term, even for those with only mild disease previously.
AMs are also increasingly recognised as having beneﬁcial
effects beyond disease control and damage prevention.
They may protect against thrombosis and loss of bone
mass, improve lipid proﬁles and improve maternal out-
comes during pregnancy.21 Thus physicians may choose
to continue long-term AMs for reasons beyond disease
control. Although our survey did not seek speciﬁcally to
examine these issues it does highlight that any future
deﬁnition of remission needs to bear in mind what
doctors do in the real world. Our study indicates that
co-treatment, duration of clinical remission and, in par-
ticular, serological activity need to be considered in any
proposed deﬁnition(s) of remission. These three factors
inﬂuence treatment decisions in patients with no
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apparent clinical disease manifestations and the more
restrictive the deﬁnition(s) are for these variables, the
smaller the pool of patients to study. One solution might
be for a series of graded deﬁnitions of remission as sug-
gested by both Franklyn et al and van Vollenhoven et al,
with increasing rigour of remission deﬁnition taking
into account disease duration, serology and AM use.22 23
This approach is supported by our current data.
Our study has a number of limitations. We had to
develop our own survey proforma as no standardised
questionnaire, which could have been modiﬁed, was
available. Although we had 30 scenarios, the variability
that we might have introduced was restricted as a larger
survey would have had a much lower response rate. We
acknowledge that further understanding is required of
the inﬂuence on decision-making of the exact order and
sequencing of medication withdrawal, dose variation,
nuancing of recency of ﬂares, extent of serological abnor-
mality and other organ involvement patterns, etc. We also
recognise that such scenarios do not fully represent real-
world practice where physicians will know their patients
well and will better understand the waxing and waning of
their disease. Also, we were not able to provide a system-
atic description of patients’ history and thus the cases
were somewhat theoretical. However, we did base cases
on real scenarios and tried to vary several items in a
standard way to understand how changing key items
inﬂuences decision-making. In addition, not all partici-
pants responded to every question stem. Finally, given the
number of respondents we did not adjust the data for
multiple comparisons. However, given the clear trends
observed across all the stems, we think our results are
generalisable and reﬂective of real-world clinical practice.
In conclusion, we found that clinicians’ approach to
withdrawing or reducing treatment in patients with SLE
in clinical remission varies substantially. Serological abnor-
malities and previous disease severity, in particular, inﬂu-
ence a clinician’s decision to reduce treatments, with
HCQ rarely being withdrawn even after a prolonged
period of remission in patients with only mild disease. It
is unusual for clinicians to withdraw all treatments, even
after a very prolonged period of clinical remission, poten-
tially exposing patients to unwanted side effects from
these medications. Any deﬁnition(s) of remission need to
consider evidence on the way in which maintenance treat-
ments are managed. Future clinical trials should also
focus on determining best practice for when and how to
safely withdraw treatment particularly in patients with
serologically active, clinically quiescent disease.
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